CMS granted the company a broad-based national coverage policy at breakneck speed and a positive preliminary payment decision to boot for the Cologuard DNA stool test. It is the first national coverage determination resulting from the FDA-CMS parallel review pilot.

A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?

President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.